Showing results (231-240 of 279) with videos related to
Sort By:
Pageof 28
The Journal of Allergy and Clinical Immunology. in Practice|June 20, 2022
Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM ConsortiumPolina Pyatilova, Cem Akin, Iván Alvarez-Twose, et al.Nature Medicine|June 5, 2019
Identification of rare-disease genes using blood transcriptome sequencing and large control cohortsLaure Frésard, Craig Smail, Nicole M Ferraro, et al.The Journal of Allergy and Clinical Immunology. in Practice|May 27, 2022
Global Classification of Mast Cell Activation Disorders: An ICD-10-CM-Adjusted Proposal of the ECNM-AIM ConsortiumPeter Valent, Karin Hartmann, Patrizia Bonadonna, et al.Journal of the National Comprehensive Cancer Network : JNCCN|October 7, 2017
NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018Ruben A Mesa, Catriona Jamieson, Ravi Bhatia, et al.The Journal of Allergy and Clinical Immunology. in Practice|August 12, 2023
The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαTPeter Valent, Gregor Hoermann, Patrizia Bonadonna, et al.Blood|February 29, 2020
Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosisLukas Ronner, Nikolai Podoltsev, Jason Gotlib, et al.Journal of the National Comprehensive Cancer Network : JNCCN|September 4, 2020
Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in OncologyAaron T Gerds, Jason Gotlib, Prithviraj Bose, et al.The Journal of Allergy and Clinical Immunology. in Practice|June 20, 2022
Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic MastocytosisJason Gotlib, Juliana Schwaab, William Shomali, et al.Journal of the American Academy of Dermatology|February 14, 2026
Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER studyFrank Siebenhaar, Sigurd Broesby-Olsen, Mariana Castells, et al.Journal of the National Comprehensive Cancer Network : JNCCN|December 14, 2016
NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017Arnel Pallera, Jessica K Altman, Ellin Berman, et al.Pageof 28